CivicaScript Expands Access to Affordable Insulin and Biosimilars in the U.S.
In a significant move to enhance healthcare affordability, CivicaScript®, a nonprofit organization committed to supplying low-cost generic drugs, has announced the introduction of two vital products in the United States: insulin glargine-yfgn and ustekinumab-aauz. This development aims to improve patient access to essential medications, particularly for those managing chronic conditions such as diabetes and inflammatory diseases.
Affordable Insulin Availability
Civica's insulin glargine-yfgn is a long-acting insulin designed for individuals with diabetes mellitus. This product is particularly groundbreaking because it is interchangeable with Lantus®, a leading insulin brand, effectively offering patients a more affordable alternative. Insulin glargine-yfgn is now available in prefilled pens at a list price of just $45 for a box of five pens, significantly lower than the prices typically seen in the market.
Additionally, CivicaScript has partnered with California's CalRx® program, allowing local pharmacies to distribute this product under the CalRx brand, further expanding its reach. CivicaScript emphasizes its commitment to transparency in drug pricing, which means their maximum price for consumers is limited to $55, although many users may pay even less depending on their insurance plans. This ongoing effort to make medications more accessible stands in stark contrast to other manufacturers' copay assistance programs, where prices can fluctuate and require complex registration processes.
Treating Chronic Inflammatory Conditions
Alongside insulin, CivicaScript has also introduced ustekinumab-aauz, a biosimilar used for treating various chronic inflammatory conditions such as plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Ustekinumab-aauz is interchangeable with the reference product Stelara®, offering patients a reliable and effective treatment option at a lower cost. The wholesale acquisition cost (WAC) for ustekinumab-aauz stands at $985 for a 12-week supply of 90 mg and $575 for a 12-week supply of 45 mg, which is accessible to CivicaScript members and partners, including health plans and pharmacy benefit managers.
Leadership Perspective
Brent J. Eberle, the President of CivicaScript, expressed pride in the company’s efforts to enhance medication affordability, stating, "We’re proud to begin the New Year by expanding access to two important biosimilars that can help lower costs for patients and health plans. Our growing portfolio shows that putting patients first isn’t just the right thing to do – it’s a proven path to delivering affordable generics and biosimilars."
This announcement not only marks a milestone for CivicaScript but also signifies an essential stride toward improving the health and well-being of patients who rely on insulin and other necessary medications to manage their conditions. CivicaScript aims to bring clarity and fairness to the healthcare system, ensuring that everyone can afford vital medications.
About CivicaScript
CivicaScript operates as a part of Civica, Inc., focusing on the outpatient medication market. The organization’s goal is to promote public health by providing essential generic medicines with a level of transparency that has previously been lacking in the pharmaceutical industry.
To learn more about CivicaScript and its mission, interested individuals can visit their official website. This initiative not only contributes to patient care but also encourages others in the pharmaceutical sector to adopt similar pricing policies, ultimately fostering a more equitable healthcare environment.
Affordable Insulin Availability
Civica's insulin glargine-yfgn is a long-acting insulin designed for individuals with diabetes mellitus. This product is particularly groundbreaking because it is interchangeable with Lantus®, a leading insulin brand, effectively offering patients a more affordable alternative. Insulin glargine-yfgn is now available in prefilled pens at a list price of just $45 for a box of five pens, significantly lower than the prices typically seen in the market.
Additionally, CivicaScript has partnered with California's CalRx® program, allowing local pharmacies to distribute this product under the CalRx brand, further expanding its reach. CivicaScript emphasizes its commitment to transparency in drug pricing, which means their maximum price for consumers is limited to $55, although many users may pay even less depending on their insurance plans. This ongoing effort to make medications more accessible stands in stark contrast to other manufacturers' copay assistance programs, where prices can fluctuate and require complex registration processes.
Treating Chronic Inflammatory Conditions
Alongside insulin, CivicaScript has also introduced ustekinumab-aauz, a biosimilar used for treating various chronic inflammatory conditions such as plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Ustekinumab-aauz is interchangeable with the reference product Stelara®, offering patients a reliable and effective treatment option at a lower cost. The wholesale acquisition cost (WAC) for ustekinumab-aauz stands at $985 for a 12-week supply of 90 mg and $575 for a 12-week supply of 45 mg, which is accessible to CivicaScript members and partners, including health plans and pharmacy benefit managers.
Leadership Perspective
Brent J. Eberle, the President of CivicaScript, expressed pride in the company’s efforts to enhance medication affordability, stating, "We’re proud to begin the New Year by expanding access to two important biosimilars that can help lower costs for patients and health plans. Our growing portfolio shows that putting patients first isn’t just the right thing to do – it’s a proven path to delivering affordable generics and biosimilars."
This announcement not only marks a milestone for CivicaScript but also signifies an essential stride toward improving the health and well-being of patients who rely on insulin and other necessary medications to manage their conditions. CivicaScript aims to bring clarity and fairness to the healthcare system, ensuring that everyone can afford vital medications.
About CivicaScript
CivicaScript operates as a part of Civica, Inc., focusing on the outpatient medication market. The organization’s goal is to promote public health by providing essential generic medicines with a level of transparency that has previously been lacking in the pharmaceutical industry.
To learn more about CivicaScript and its mission, interested individuals can visit their official website. This initiative not only contributes to patient care but also encourages others in the pharmaceutical sector to adopt similar pricing policies, ultimately fostering a more equitable healthcare environment.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.